Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in research using resting EEG/cognitive EEG (ERP) brain scans, collected on its FDA 510(k)-cleared Evoke System, to potentially distinguish among the three main subtypes of attention-deficit/hyperactivity disorder (ADHD): hyperactive and impulsive, inattentive, and combined.
Currently, a diagnosis of adult ADHD is based on meeting the following general symptom-based criteria: symptoms must be present in two or more settings, such as home, work, or school; they must clearly interfere with functioning in social, work, or school-related activities; they cannot be better explained by another mental health condition, such as depression or anxiety; and they must not occur only during the course of a psychotic disorder like schizophrenia.
In a statement, Gil Issachar, CTO of Firefly, commented, “While there has been significant progress made in the treatment of ADHD over the years, there is no question that significant unmet need remains, particularly after a general diagnosis of the disorder has been made. For example, some types of ADHD respond well to stimulants, while others don’t and neurofeedback therapy may be recommended instead. Firefly’s EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans. We believe that the technology also opens the door to ongoing treatment monitoring—allowing clinicians to objectively track whether an intervention is working at the neurological level.”
Greg Lipschitz, CEO of Firefly, said, “This latest Firefly cognitive brain biomarker discovery serves as another demonstration of how we are harnessing the power of AI and EEG/ERP to potentially transform neuroscience and clinical development. Moving forward, armed with a growing foundation of brain scan data and important access to NVIDIA GPU acceleration to power next-generation EEG/ERP processing, we believe that we are on the right path to making even more breakthroughs in cognitive brain biomarker discovery, as well as to fulfilling our goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
Firefly’s methodology is supported by prior peer-reviewed research, including a study published in the journal Frontiers in Psychiatry demonstrating the diagnostic utility of EEG-based brain activity flow pattern analysis in ADHD patients.
